CA-ANDERSEN-GLOBAL
26.8.2020 13:09:04 CEST | Business Wire | Pressemeddelelse
De latinamerikanske medlemsfirmaer i Andersen Global vil nu operere under navnet ”Andersen”, hvilket styrker organisationens position som en one-stop-shop for skattemæssige og juridiske tjenester globalt. Meddelelsen kommer mindre end to måneder efter, at de europæiske medlemsfirmaer i Andersen Global antog Andersen-navnet.
Andersen Globals medlemsfirmaer i Brasilien, Ecuador, Guatemala, Mexico og Uruguay, der tidligere opererede under navnene, ”Andersen Tax” og ”Andersen Tax & Legal,” har nu Andersen som deres navn sammen med de nye medlemsfirmaer, MODO Law og GSRC i Argentina, der blev medlemsfirmaer i organisationen tidligere på året.
Andersen Global fortsætter med at betragte udvidelse af både sit fodaftryk i Latinamerika og sin nyetablerede platform i Caribien som høje prioriteter. I Latinamerika har den globale organisation også en tilstedeværelse i Chile, Colombia, Costa Rica, El Salvador, Honduras, Nicaragua, Panama, Paraguay og Peru gennem sine samarbejdsfirmaer, og har tilføjet samarbejdsfirmaer i 11 lande i Caribien i løbet af de sidste seks måneder.
”Vores ekspansion er drevet af kundeservice, og vores målsætning er ikke at være det største firma, snarere handler vores fokus om vores engagement i at opbygge et firma, hvor kunder får uovertrufne skattemæssige og juridiske tjenester på en sømløs måde overalt i verden,” sagde bestyrelsesformand for Andersen Global og administrerende direktør for Andersen, Mark Vorsatz. ”Vores organisation er ikke kun dedikeret til vores kunder, men også til at investere i vores medarbejdere og den næste generation. Vi deler alle de samme værdier og den samme vision uanset grænser, og det er kun passende, at dette også afspejles i vores navn.”
Organisationens rejse begyndte i 2002, da 23 tidligere Arthur Andersen-partnere oprettede skattefirmaet WTAS. I 2014 antog det amerikanske medlemsfirma navnet “Andersen Tax” og overgik for nylig til Andersen-navnet i 2019. Den globale organisation er vokset eksponentielt siden etableringen af Andersen Global (tidligere WTAS Global) af det grundlæggende amerikanske medlem Andersen Tax LLC i 2013. Efter lanceringen af sin globale platform i Europa debuterede Andersen Global i Latinamerika i 2015. Regionen er siden vokset til mere end 34 lokaliteter, 1.000 skatte- og juraeksperter, og 90 partnere i dag.
Leonardo Mesquita, regional administrerende direktør for Latinamerika tilføjede, ”Vores organisations fundament er baseret på vores fælles vision om at forblive uafhængige og levere sømløse, synergistiske tjenester til vores kunder globalt. Vi glæder os til at have et navn, der afspejler det, vi allerede ved – vi er ét firma.”
I løbet af det næste år fortsætter medlemsfirmaer globalt med at antage Andersen-navnet, mens Andersen Global fortsætter sin ekspansionsindsats på vigtige markeder, herunder Caribien, Latinamerika, Afrika og Mellemøsten.
Andersen Global er en international sammenslutning af juridisk separate, uafhængige medlemsfirmaer, bestående af skatte- og juraeksperter fra hele verden. Siden oprettelsen i 2013 af det amerikanske medlemsfirma Andersen Tax LLC har Andersen Global nu over 6.000 eksperter globalt og er repræsenteret på over 191 lokaliteter via sine medlems- og samarbejdsfirmaer.
Originalsprogsudgaven af denne bekendtgørelse er den officielle, autoriserede version. Oversættelserne er kun tænkt som en hjælp og bør sammenholdes med kildesprogsteksten, der som den eneste er juridisk bindende.
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20200826005393/da/
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum
